Elena Kotsiliti,Valentina Leone,Svenja Schuehle,Olivier Govaere,Hai Li,Monika J Wolf,Helena Horvatic,Sandra Bierwirth,Jana Hundertmark,Donato Inverso,Laimdota Zizmare,Avital Sarusi-Portuguez,Revant Gupta,Tracy O'Connor,Anastasios D Giannou,Ahmad Mustafa Shiri,Yehuda Schlesinger,Maria Garcia Beccaria,Charlotte Rennert,Dominik Pfister,Rupert Öllinger,Iana Gadjalova,Pierluigi Ramadori,Mohammad Rahbari,Nuh Rahbari,Marc E Healy,Mirian Fernández-Vaquero,Neda Yahoo,Jakob Janzen,Indrabahadur Singh,Chaofan Fan,Xinyuan Liu,Monika Rau,Martin Feuchtenberger,Eva Schwaneck,Sebastian J Wallace,Simon Cockell,John Wilson-Kanamori,Prakash Ramachandran,Celia Kho,Timothy J Kendall,Anne-Laure Leblond,Selina J Keppler,Piotr Bielecki,Katja Steiger,Maike Hofmann,Karsten Rippe,Horst Zitzelsberger,Achim Weber,Nisar Malek,Tom Luedde,Mihael Vucur,Hellmut G Augustin,Richard Flavell,Oren Parnas,Roland Rad,Olivier Pabst,Neil C Henderson,Samuel Huber,Andrew Macpherson,Percy Knolle,Manfred Claassen,Andreas Geier,Christoph Trautwein,Kristian Unger,Eran Elinav,Ari Waisman,Zeinab Abdullah,Dirk Haller,Frank Tacke,Quentin M Anstee,Mathias Heikenwalder

Abstract:Background & aims: The progression of non-alcoholic steatohepatitis (NASH) to fibrosis and hepatocellular carcinoma (HCC) is aggravated by auto-aggressive T cells. The gut-liver axis contributes to NASH, but the mechanisms involved and the consequences for NASH-induced fibrosis and liver cancer remain unknown. We investigated the role of gastrointestinal B cells in the development of NASH, fibrosis and NASH-induced HCC. Methods: C57BL/6J wild-type (WT), B cell-deficient and different immunoglobulin-deficient or transgenic mice were fed distinct NASH-inducing diets or standard chow for 6 or 12 months, whereafter NASH, fibrosis, and NASH-induced HCC were assessed and analysed. Specific pathogen-free/germ-free WT and μMT mice (containing B cells only in the gastrointestinal tract) were fed a choline-deficient high-fat diet, and treated with an anti-CD20 antibody, whereafter NASH and fibrosis were assessed. Tissue biopsy samples from patients with simple steatosis, NASH and cirrhosis were analysed to correlate the secretion of immunoglobulins to clinicopathological features. Flow cytometry, immunohistochemistry and single-cell RNA-sequencing analysis were performed in liver and gastrointestinal tissue to characterise immune cells in mice and humans. Results: Activated intestinal B cells were increased in mouse and human NASH samples and licensed metabolic T-cell activation to induce NASH independently of antigen specificity and gut microbiota. Genetic or therapeutic depletion of systemic or gastrointestinal B cells prevented or reverted NASH and liver fibrosis. IgA secretion was necessary for fibrosis induction by activating CD11b+CCR2+F4/80+CD11c-FCGR1+ hepatic myeloid cells through an IgA-FcR signalling axis. Similarly, patients with NASH had increased numbers of activated intestinal B cells; additionally, we observed a positive correlation between IgA levels and activated FcRg+ hepatic myeloid cells, as well the extent of liver fibrosis. Conclusions: Intestinal B cells and the IgA-FcR signalling axis represent potential therapeutic targets for the treatment of NASH. Impact and implications: There is currently no effective treatment for non-alcoholic steatohepatitis (NASH), which is associated with a substantial healthcare burden and is a growing risk factor for hepatocellular carcinoma (HCC). We have previously shown that NASH is an auto-aggressive condition aggravated, amongst others, by T cells. Therefore, we hypothesized that B cells might have a role in disease induction and progression. Our present work highlights that B cells have a dual role in NASH pathogenesis, being implicated in the activation of auto-aggressive T cells and the development of fibrosis via activation of monocyte-derived macrophages by secreted immunoglobulins (e.g., IgA). Furthermore, we show that the absence of B cells prevented HCC development. B cell-intrinsic signalling pathways, secreted immunoglobulins, and interactions of B cells with other immune cells are potential targets for combinatorial NASH therapies against inflammation and fibrosis.

Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH

Macrophage Raptor Deficiency-Induced Lysosome Dysfunction Exacerbates Nonalcoholic Steatohepatitis

XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis

Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation

Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling

Microbiota‐Driven Activation of Intrahepatic B Cells Aggravates NASH Through Innate and Adaptive Signaling

A pathogenic role for regulatory T cells in chronic liver disease

Abstract 2869: The role of regulatory T cells in NASH-mediated HCC development

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Kupffer Cells Undergo Fundamental Changes during the Development of Experimental NASH and Are Critical in Initiating Liver Damage and Inflammation

Dysfunctional T Follicular Helper Cells Cause Intestinal and Hepatic Inflammation in NASH

CX3CL1/CX3CR1 interaction protects against lipotoxicity-induced nonalcoholic steatohepatitis by regulating macrophage migration and M1/M2 status

CD4+ T cell activation and inflammation in NASH-related fibrosis

Myeloid cell MHC I expression drives CD8+ T cell activation in nonalcoholic steatohepatitis

NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosis

CXCL5 promotes lipotoxicity of hepatocytes through upregulating NLRP3/Caspase-1/IL-1β signaling in Kupffer cells and exacerbates nonalcoholic steatohepatitis in mice

Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis

The Role of Neutrophil Extracellular Traps in Nonalcoholic Steatohepatitis-Associated Hepatocellular Carcinoma

CXC Chemokine Receptor 3 Promotes Steatohepatitis in Mice Through Mediating Inflammatory Cytokines, Macrophages and Autophagy.

Differential Lipidomics, Metabolomics and Immunological Analysis of Alcoholic and Non-Alcoholic Steatohepatitis in Mice

The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH)